secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001558370-25-008433
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress closes sale of Checkpoint to Sun Pharma; receives ~$28M cash plus milestones
--------------------------------------------------------------------------------

- Checkpoint merged into Sun Pharma on May 30, 2025; deconsolidated from Fortress.
- Fortress gets ~$28.0M cash at close, up to $4.8M regulatory milestone, and quarterly royalty of 2.5% on certain product net sales.
- Pro forma gain on deconsolidation is $26.6M; pro forma net loss attributable to common stockholders improves from $(0.48) to $0.57 per share for Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/0001558370-25-008433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/fbio-20250530x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer